Grifols, ES0171996087

Barron's lists EUR 15.55 average target for Grifols stock

Published on 10/26/2026 at 16:15 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

The 52-week high is EUR 11.70 on October 26, 2026. Grifols stock costs EUR 10.58 on October 26, 2026, up 4.75 percent versus the Xetra close.

Analyst target and operating figures

Barron's listed an average EUR 15.55 target from 13 ratings on October 26, 2026.
Grifols reported first-half net profit of EUR 227 million, up 28.70 percent, on July 28, 2026.
Grifols stock costs EUR 10.58 at Lang & Schwarz on October 26, 2026 at 4:06 p.m. CET, 4.75 percent above the Xetra close of October 23, 2026.
The market capitalization stood at EUR 6.04 billion on October 26, 2026.

Grifols, ES0171996087, Illustration mit AI erstellt.

Grifols (ISIN ES0171996087) had an average analyst target of EUR 15.55 from 13 ratings on October 26, 2026, according to Barron's. The average target stood 46.98 percent above the EUR 10.58 price. Grifols was trading at EUR 10.58 at Lang & Schwarz on October 26, 2026 at 4:06 p.m. CET, up 4.75 percent versus the Xetra close of October 23, 2026 at EUR 10.10.

Profit growth supplies operating context

Grifols reported first-half net profit of EUR 227 million, up 28.70 percent from the first half of 2025, in its July 28, 2026 investor release. The company also said first-half revenue rose 2.60 percent to EUR 3.57 billion, with Biopharma revenue increasing 5.40 percent. These figures place the analyst target against a business that expanded profit faster than revenue during the first half.

Stock remains below the yearly high

The EUR 10.58 Lang & Schwarz price was 9.57 percent below the 52-week high of EUR 11.70 on October 26, 2026. Barron's listed a day range of EUR 10.20 to EUR 10.53 and volume of 1.07 million shares for the same date. The market capitalization was EUR 6.04 billion, while the trailing price-to-earnings ratio was 15.83.

Valuation leaves a wide target spread

The average EUR 15.55 target implies a wide gap above the market price, but the range of analyst views matters more than the average alone. Barron's listed the average score as Sell alongside the 13-rating target on October 26, 2026. Grifols operates in healthcare and focuses on plasma-derived therapies, a business profile that makes earnings growth and financing costs central valuation variables.

Price and investor perspective

The stock's 4.75 percent premium to the Xetra close gives the October 26 quotation more weight than the prior week's EUR 10.10 closing level. The distance to the 52-week high and the EUR 15.55 average target leave two separate reference points for assessing the market's current valuation.

Trading level in Germany

Grifols was trading at EUR 10.58 at Lang & Schwarz on October 26, 2026 at 4:06 p.m. CET, 4.75 percent above the Xetra close of October 23, 2026 at EUR 10.10. The further course of trading is shown by the continuously updated real-time quote of Grifols stock.